In order to accelerate access to medicines for patients across the globe, we enter into various kinds of partnerships and collaboration, including licensing.
Most of our licensing agreements so far have been of three categories:
In-licensing: To increase access to critical medicines for patients we license products developed and manufactured by other companies and supply them to patients in markets where we have a strong marketing and sales network. This helps patients get access to medicines which were not available to them otherwise.
Out-licensing: We create, develop and manufacture certain medicines that we may then license to other pharmaceutical companies to market and sell in particular markets. This allows our products to reach patients they otherwise would not.
Co-development: To further increase access to medicines for patients, in some cases we may develop a product in partnership with another firm. In most cases we market the developed product in countries where we have a major presence.